Contact


Mailing Address

Donate

Your tax deductible gift in any amount helps support our efforts to advocate for more research, better treatments, and ultimately, a cure for IH.

Donate
 

Author:Hypersomnia Foundation

Idiopathic Hypersomnia Standard Characteristics

It’s often a struggle to describe to others – sometimes to doctors – the essence of idiopathic hypersomnia. Now, the Hypersomnia Foundation presents Idiopathic Hypersomnia Standard Characteristics. This one-page document, reviewed and approved by our Medical Advisory Board, summarizes the common characteristics of IH. We hope...

Continue Reading

Arise Clinical Trial

CLINICAL TRIAL ENROLLING PATIENTS WITH IDIOPATHIC HYPERSOMNIA AND NARCOLEPSY TYPE 2 Balance Therapeutics is evaluating an investigational new drug BTD-001, to treat excessive daytime sleepiness in individuals diagnosed with idiopathic hypersomnia (IH) or narcolepsy type 2 (Na-2). A Phase 2 clinical trial is currently enrolling Na-2 subjects at 26...

Continue Reading

Get “Somnusnooze”, our monthly e-newsletter

Sign up to receive HF updates, news from the world of sleep research, first-person stories, and more.

You will receive an email from info@hypersomniafoundation.org (please check your junk/spam folder if needed) to confirm your subscription to our newsletter through MailChimp. You are not subscribed until you confirm. We recommend that you add info@hypersomniafoundation.org to your contacts and/or safe email list (whitelist) to ensure you receive all future newsletters. Thank you for your interest in the Hypersomnia Foundation!